JAMA Oncology

@JAMAOnc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

Chicago, IL

Joined September 2014

511Following

49KFollowers

JAMA Oncology@JAMAOnc · 51 m

While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4m3Eesv @AlexSherryMD @oncology_bg @PavlosMsaouel @ebludmir

JAMAOnc's tweet image. While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4m3Eesv @AlexSherryMD @oncology_bg @PavlosMsaouel @ebludmir

438

JAMA Oncology@JAMAOnc · 24 h

From @JAMA_current: Approximately 21 000 women are diagnosed with ovarian cancer annually in the US. This Review summarizes the diagnosis and management of high-grade serous ovarian cancer. ja.ma/44I2mv9

JAMAOnc's tweet image. From @JAMA_current: Approximately 21 000 women are diagnosed with ovarian cancer annually in the US.

This Review summarizes the diagnosis and management of high-grade serous ovarian cancer.

ja.ma/44I2mv9

3.0K

JAMA Oncology@JAMAOnc · Jul 22

Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. ja.ma/3IDBKmq @josephcmurray

JAMAOnc's tweet image. Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. ja.ma/3IDBKmq @josephcmurray

2.0K

JAMA Oncology@JAMAOnc · Jul 21

Most viewed this week from @JAMAOnc: Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials. ja.ma/3TMQ4eI

JAMAOnc's tweet image. Most viewed this week from @JAMAOnc:

Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials.

ja.ma/3TMQ4eI

3.0K

JAMA Oncology@JAMAOnc · Jul 21

Among two U.S prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024. ja.ma/3TGuJUa @monda_steven @4rnav @MUSICurology @wandering_gu

JAMAOnc's tweet image. Among two U.S prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024. ja.ma/3TGuJUa @monda_steven @4rnav @MUSICurology @wandering_gu

2.0K

JAMA Oncology@JAMAOnc · Jul 20

Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. ja.ma/3GSEPOQ

JAMAOnc's tweet image. Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy.

ja.ma/3GSEPOQ

8.0K

JAMA Oncology@JAMAOnc · Jul 20

Review: Research advancements in acute lymphoblastic leukemia (ALL) have led to improved outcomes through the use of targeted therapies and immunotherapies, reducing the reliance on prolonged chemotherapy. ja.ma/3IwWcW1

JAMAOnc's tweet image. Review: Research advancements in acute lymphoblastic leukemia (ALL) have led to improved outcomes through the use of targeted therapies and immunotherapies, reducing the reliance on prolonged chemotherapy. ja.ma/3IwWcW1

2.0K

JAMA Oncology@JAMAOnc · Jul 19

From @JAMA_current: Early-onset gastrointestinal cancers are among the largest subset of early-onset cancers globally. This JAMA Review summarizes current evidence on early-onset gastrointestinal cancers. ja.ma/3GSXvOo @KimmieNgMD @DanaFarber

JAMAOnc's tweet image. From @JAMA_current: Early-onset gastrointestinal cancers are among the largest subset of early-onset cancers globally.

This JAMA Review summarizes current evidence on early-onset gastrointestinal cancers.

ja.ma/3GSXvOo

@KimmieNgMD @DanaFarber

7.0K

JAMA Oncology@JAMAOnc · Jul 19

A woman in her 50s with a history of hemochromatosis, psoriasis, and type 2 diabetes presented with a 3-month history of abdominal pain, weight loss, and a large palpable fixed abdominal mass. What is your diagnosis? ja.ma/40XDPQc

JAMAOnc's tweet image. A woman in her 50s with a history of hemochromatosis, psoriasis, and type 2 diabetes presented with a 3-month history of abdominal pain, weight loss, and a large palpable fixed abdominal mass. What is your diagnosis? ja.ma/40XDPQc

1.0K

JAMA Oncology@JAMAOnc · Jul 19

3.0K

JAMA Oncology@JAMAOnc · Jul 18

Cell-free DNA (cfDNA) testing could improve colorectal cancer detection and reduce mortality in Canada, but it requires higher participation rates to be effective compared to current screening methods. ja.ma/46KoTZy @jonathanloree

JAMAOnc's tweet image. Cell-free DNA (cfDNA) testing could improve colorectal cancer detection and reduce mortality in Canada, but it requires higher participation rates to be effective compared to current screening methods. ja.ma/46KoTZy @jonathanloree

2.0K

JAMA Oncology@JAMAOnc · Jul 17

In the post–COVID-19 period, there was a reduction in annual breast cancer surveillance imaging for early-stage breast cancer patients, though recurrence rates remained consistent with pre–COVID-19 levels. ja.ma/40oJ1fW

JAMAOnc's tweet image. In the post–COVID-19 period, there was a reduction in annual breast cancer surveillance imaging for early-stage breast cancer patients, though recurrence rates remained consistent with pre–COVID-19 levels. ja.ma/40oJ1fW

808

JAMA Oncology@JAMAOnc · Jul 17

Among cancer patients, receiving #COVID19 booster vaccines led to a 29-30% reduction in hospitalizations and ICU admissions. ja.ma/44OHvVG

JAMAOnc's tweet image. Among cancer patients, receiving #COVID19 booster vaccines led to a 29-30% reduction in hospitalizations and ICU admissions. ja.ma/44OHvVG

1.0K

JAMA Oncology@JAMAOnc · Jul 17

Among cancer patients, #COVID19 poses heightened risks particularly for those with hematologic malignancies and underlying health issues, while vaccination reduces hospitalization chances. ja.ma/4o055rw @aakonc

JAMAOnc's tweet image. Among cancer patients, #COVID19 poses heightened risks particularly for those with hematologic malignancies and underlying health issues, while vaccination reduces hospitalization chances. ja.ma/4o055rw @aakonc

1.0K

JAMA Oncology@JAMAOnc · Jul 16

Although broad genomic profiling use in newly diagnosed metastatic cancer patients increased from 2020 to 2022, it remained below 50% overall. ja.ma/4k16T01

JAMAOnc's tweet image. Although broad genomic profiling use in newly diagnosed metastatic cancer patients increased from 2020 to 2022, it remained below 50% overall. ja.ma/4k16T01

2.0K

JAMA Oncology@JAMAOnc · Jul 15

The use of certain oncology medications decreased after negative confirmatory trials and @US_FDA withdrawal of accelerated approval indications. ja.ma/3ZzjO1T @amarkelkar @bnrome

JAMAOnc's tweet image. The use of certain oncology medications decreased after negative confirmatory trials and @US_FDA withdrawal of accelerated approval indications. ja.ma/3ZzjO1T @amarkelkar @bnrome

3.0K

JAMA Oncology@JAMAOnc · Jul 14

Most viewed this week from @JAMAOnc: Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival. ja.ma/45Zg2mu

JAMAOnc's tweet image. Most viewed this week from @JAMAOnc:

Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival.

ja.ma/45Zg2mu

4.0K

JAMA Oncology@JAMAOnc · Jul 14

Despite the value of genomic assays in personalizing breast cancer treatment, this review found that they do not fully address racial and ethnic disparities in outcomes. ja.ma/3HN0gBe @YAbdouMD

JAMAOnc's tweet image. Despite the value of genomic assays in personalizing breast cancer treatment, this review found that they do not fully address racial and ethnic disparities in outcomes. ja.ma/3HN0gBe @YAbdouMD

1.0K

JAMA Oncology@JAMAOnc · Jul 13

The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. ja.ma/4k5ldos @Pike_lab

JAMAOnc's tweet image. The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. ja.ma/4k5ldos @Pike_lab

6.0K

JAMA Oncology@JAMAOnc · Jul 12

Viewpoint: Cancer patients frequently face costly dental complications, particularly in head and neck cancers, requiring improved insurance coverage to reduce financial burdens. ja.ma/3U7WhSs

JAMAOnc's tweet image. Viewpoint: Cancer patients frequently face costly dental complications, particularly in head and neck cancers, requiring improved insurance coverage to reduce financial burdens.

ja.ma/3U7WhSs

1.0K